Scarica l'app Stockscreener
15.62
2.01%
-0.32
Dopo l'orario di chiusura:
15.79
0.17
+1.09%
Uniqure N V Borsa (QURE) Ultime notizie
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing - GlobeNewswire
QURE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
Holzer & Holzer, LLC Reminds Investors of April 13, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Kyndryl Holdings, Inc. (KD) and uniQure N.V. (QURE) - lincolnjournal.com
Holzer & Holzer, LLC Reminds Investors of April 13, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Kyndryl Holdings, Inc. (KD) and uniQure N.V. (QURE) - GlobeNewswire Inc.
uniQure (NASDAQ:QURE) Shares Gap DownShould You Sell? - MarketBeat
QURE Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in uniQure N.V. Securities Lawsuit -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Class Action Filed Against uniQure N.V. (QURE) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial DesignHagens Berman - PR Newswire
uniQure N.V. (NASDAQ:QURE) Sees Significant Growth in Short Interest - MarketBeat
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
Farallon Capital Management LLC Raises Position in uniQure N.V. $QURE - MarketBeat
Darwin Global Management Ltd. Purchases New Shares in uniQure N.V. $QURE - MarketBeat
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - GuruFocus
uniQure N.V. $QURE is Boxer Capital Management LLC's 2nd Largest Position - MarketBeat
Boone Capital Management LLC Makes New Investment in uniQure N.V. $QURE - MarketBeat
uniQure N.V. Stock (ISIN: IL0011559904) Faces Pressure Amid Gene Therapy Setbacks - AD HOC NEWS
Quinn Opportunity Partners LLC Acquires New Stake in uniQure N.V. $QURE - MarketBeat
uniQure N.V. $QURE Position Decreased by Integral Health Asset Management LLC - MarketBeat
Avoro Capital Advisors LLC Has $259.42 Million Position in uniQure N.V. $QURE - MarketBeat
QURE INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of uniQure N.V. Investors - ACCESS Newswire
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - PR Newswire
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz - GuruFocus
UniQure to rally around 92%? Here are 10 top analyst forecasts for Wednesday - MSN
QUREuniQure N.V Stock Price and Quote - Finviz
uniQure N.V.Ordinary Shares (NQ: QURE - The Chronicle-Journal
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline - PR Newswire
uniQure (NASDAQ:QURE) Trading Down 8.3%Here's Why - MarketBeat
Why (QURE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
QURE jumps 20% – analysts upgrade stock on Huntington’s disease therapy update, retail eyes $150 - MSN
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
QURE Shareholder Alert: April 13, 2026 Lead Plaintiff Deadline in uniQure N.V. Securities Class ... - Bluefield Daily Telegraph
QURE Shareholder Alert: April 13, 2026 Lead Plaintiff - GlobeNewswire
Rosalind Advisors Inc. Acquires New Shares in uniQure N.V. $QURE - MarketBeat
UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh - Sahm
uniQure (QURE) Upgraded to Outperform by Mizuho, Price Target Ra - GuruFocus
uniQure upgraded at Mizuho on improved outlook for Huntington's asset AMT-130 - Seeking Alpha
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class ActionHagens Berman - PR Newswire
A Unique Situation For UniQure (QURE) - Seeking Alpha
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
QURE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
HC Wainwright Has Negative Forecast for uniQure Q1 Earnings - MarketBeat
Mizuho upgrades UniQure NV (QURE) - MSN
Atika Capital Management LLC Invests $5.25 Million in uniQure N.V. $QURE - MarketBeat
Lawsuit filed for Investors who lost money with shares of uniQure N.V. (NASDAQ: QURE) - openPR.com
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - GlobeNewswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
uniQure N.V. (QURE) Investors: April 13, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP - NewMediaWire
User - The Chronicle-Journal
QURE LAWSUIT ALERT: Levi & Korsinsky Notifies uniQure N.V. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman - marketscreener.com
QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
uniQure (NASDAQ:QURE) Upgraded at Mizuho - MarketBeat
uniQure (QURE) Gains Momentum with Mizuho's Rating Upgrade and P - GuruFocus
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Mizuho Securities Upgrades UniQure NV(QURE.US) to Buy Rating, Raises Target Price to $35 - 富途牛牛
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. - GlobeNewswire
Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike—Hims & Hers, Ovintiv, Uniqure In Focus - Sahm
Why Is uniQure Stock Skyrocketing Monday? - Sahm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE - ChartMill
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE - FinancialContent
uniQure N.V. Sued for Securities Law ViolationsInvestors Shou - GuruFocus
0.02%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):